Vidar has over 25 years experience in both the pharmaceutical and biotech industry within non-clinical and clinical development, and medical affairs covering different therapeutic areas including neuroscience, infectious diseases, and immune-mediated inflammatory conditions. Also a clinical assessor of vaccines and antivirals at the Swedish Medical Products Agency (MPA).
Key Areas Of Expertise
- Strategic planning of clinical development programmes for a wide variety of therapeutic indications
- Neurosciences (neurology, neurodegeneration)
- Cystic fibrosis
- Allergic asthma
- HIV
- Translational research and early clinical trial design
- Target product profiles
- Clinical assessor of vaccines and antivirals (HCV, HBV, HIV)
- Clinical advisory board management
Before NDA
Vidar has extensive experience in management positions within large pharmaceutical companies, as well as life science startups.
He holds an MD, PhD from Karolinska Institutet, Sweden, his research focused on Epstein-Barr virus-induced transformation of B lymphocytes.
Recent Publications
Bahnan W,, Wrighton S., Sundwall M., Bläckberg A., Larsson O., Höglund U., Khakzad H., Godzwon M., Walle M., Elder E., Söderlund Strand A., Happonen L., André O., Kumra Ahnlide J., Hellmark T., Wendel-Hansen V., Pa Wallin R., Malmström J., Malmström L., Ohlin M., Rasmussen M., Nordenfelt P. Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2. Front Immunol: 12, 808932 (2022).
Pollard RB., Rockstroh JK., Pantaleo G., Asmuth DM., Peters B., Lazzarin A., Garcia F., Ellefsen K., Podzamczer D., van Lunzen J., Arastéh K., Schürmann D., Clotet B., Hardy WD., Mitsuyasu R., Moyle G., Plettenberg A., Fisher M., Fätkenheuer G., Fischl M., Taiwo B., Baksaas I., Jolliffe D., Persson S., Jelmert Ø., Hovden AO., Sommerfelt MA., Wendel-Hansen V., Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomized, double-blind, placebo-controlled trial. The Lancet Infectious Diseases: 14 (4), 291-300 (2014).
